Polypharmacy and chronic pain: Harm exposure is not all about the opioids

Pain Medicine (United States)

Volumn 16, Issue 3, 2015, Pages 472-479

  Giummarra, Melita J ^a,b   Gibson, Stephen J ^b,c   Allen, Amy R ^b   Pichler, Anne Sophie ^b   Arnold, Carolyn A ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b CAULFIELD HOSPITAL   (Australia)

^c NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

Author keywords

Analgesia; Chronic pain; Detriment; Harm; Opioids; Polypharmacy; Risk

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; OPIATE; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; ANALGESIA; ARTICLE; CHRONIC PAIN; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE DURATION; DRUG EXPOSURE; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION QUANTIFICATION SCALE III; PAIN ASSESSMENT; POLYPHARMACY; RATING SCALE; SCORING SYSTEM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS; ANALGESICS, OPIOID; ANTICONVULSANTS; CHRONIC PAIN; COHORT STUDIES; COMBINED MODALITY THERAPY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN MANAGEMENT; POLYPHARMACY;

EID: 84925243591     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12586     Document Type: Article

References (27)

1. MBF Foundation, University of Sydney Pain Management Research Institute. The high price of pain: The economic impact of persistent pain in Australia. Sydney; 2007.
2. Arnold C, Giummarra M, La Porte E, Gibson SJ. Higher medication use is associated with poorer clinical presentation and psychosocial adjustment in patients with persistent pain. 14th World Congress on Pain. Milan; 2012.
3. Annemans L. Pharmacoeconomic impact of adverse events of long-term opioid treatment for the management of persistent pain. Clin Drug Investig 2011;31:73-86.
4. Hall WD, Farrell MP. Minimising the misuse of oxycodone and other pharmaceutical opioids in Australia. Med J Aust 2011;195:248-249.
5. Vuong C, Van Uum SHM, O'Dell LE, Lutfy K, Friedman TC. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev 2010;31:98-132.
6. Ram KC, Eisenberg E, Haddad M, Pud D. Oral opioid use alters DNIC but not cold pain perception in patients with chronic pain-New perspective of opioid-induced hyperalgesia. Pain 2008;139:431-438.
7. Roxburgh A, Bruno R, Larance B, Burns L. Prescription of opioid analgesics and related harms in Australia. Med J Aust 2011;195:280-284.
8. National Drug and Alcohol Research Centre. A Review of Opioid Prescribing in Tasmania: A Blueprint for the Future. Sydney: University of New South Wales; 2012.
9. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med 2010;363:1981-1985.
10. Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev 2012;(7):CD008943.
11. Kindler LL, Jones KD, Perrin N, Bennett RM. Risk factors predicting the development of widespread pain from chronic back or neck pain. J Pain 2010;11:1320-1328.
12. Frei M. Opioid dependence: Management in general practice. Aust Fam Physician 2010;39:548-552.
13. Harden RN, Weinland SR, Remble TA, etal. Medication Quantification Scale version III: Update in medication classes and revised detriment weights by survey of American Pain Society physicians. J Pain 2005;6:364-371.
14. Guck TP, Fleischer T, Pohren EJ, etal. The Medication Quantification Scale: Measurement of mediation usage at a multidisciplinary pain center. J Back Musculoskelet Rehabil 1999;13:33-38.
15. Dick BD, Rashiq S, Verrier MJ, Ohinmaa A, Zhang J. Symptom burden, medication detriment, and support for the use of the 15D health-related quality of life instrument in a chronic pain clinic population. Pain Res Treat 2011;2011:1-7. Article ID: 809071.
16. Merskey H, Lindblom U, Mumford JM, Nathan PW, Sunderland S. Pain Terms: A Current List with Definitions and Notes on Usage. Washington, DC: International Association for the Study of Pain; 2011.
17. Masters Steedman S, Middaugh SJ, Kee WG, etal. Chronic-pain medication: Equivalence levels and method of quantifying usage. Clin J Pain 1992;8:204-214.
18. Gallizzi M, Gagnon C, Harden RN, Stanos S, Khan A. Medication Quantification Scale version III: Internal validation of detriment weights using a chronic pain population. Pain Pract 2008;8:1-4.
19. Aldenderfer MS, Blash-Weld RK. Cluster Analysis. Beverly Hills: Sage Press; 1984.
20. O'Callaghan T. Cure all no more. New Sci 2014;(2971):34-37.
21. Richarz U, Jacobs A, Spina E. How frequently are contraindicated or warned against combinations of drugs prescribed to patients receiving long-term opioid therapy for chronic pain? Pharmacoepidemiol Drug Saf 2012;21:453-462.
22. Pergolizzi J, Boger RH, Budd K, etal. Opioids and the management of chronic severe pain in the elderly: Consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008;8:287-313.
23. Reisfield GM, Webster LR. Benzodiazepines in long-term opioid therapy. Pain Med 2013;14:1441-1446.
24. Masters-Steedman S, Middaugh SJ, Kee WG, etal. Chronic-pain medications: Equivalence levels and method of quantifying usage. Clin J Pain 1992;8:204-214.
25. Gallagher RM. Management of neuropathic pain-Translating mechanistic advances and evidence-based research into clinical practice. Clin J Pain 2006;22:S2-8.
26. Kroenke K, Krebs EE, Bair MJ. Pharmacotherapy of chronic pain: A synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry 2009;31:206-219.
27. Mao J, Gold MS, Backonja MM. Combination drug therapy for chronic pain: A call for more clinical studies. J Pain 2011;12:157-166.